Parkinson's disease (PD) affects about 2% of people aged 70 and older. Over the next 20 years, the number of individuals with PD is expected to triple. There are various theories explaining this increase,

A study found that those with upper gastrointestinal damage are 76% more likely to develop Parkinson's disease, signaling a potential paradigm shift in how the disease is studied.

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

Higher exposure to air pollution increases the risk for Parkinson's disease (PD), according to a study published online Sept. 16 in JAMA Network Open.

The “Parkinson’s Belt” is a series of regions in the U.S. with unusually high rates of the disease. Some scientists believe that environmental factors play a major role in who gets Parkinson’s.

Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By encouraging the kidneys to eliminate sugar from the body through urine, they reduce blood sugar.

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 diabetes.